1 week Ago By Defense World Staff
JPMorgan Chase & Co. decreased its position in shares of Bio-Rad Laboratories, Inc. ( NYSE:BIO – Free Report ) by 12.
9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,148 shares of the medical research company’s stock after selling 6,988 shares during the quarter. JPMorgan Chase & Co.
owned about 0.17% of Bio-Rad Laboratories worth $15,489,000 as of its most recent filing with the Securities & Exchange Commission. Other institutional investors also recently modified their holdings of the company.
Quantinno Capital Management LP bought a new position in shares of Bio-Rad Laboratories in the third quarter valued at $403,000. Wellington Management Group LLP lifted its position in Bio-Rad Laboratories by 56.1% in the 3rd quarter.
Wellington Management Group LLP now owns 10,016 shares of the medical research company’s stock valued at $3,351,000 after acquiring an additional 3,601 shares in the last quarter. MML Investors Services LLC boosted its stake in Bio-Rad Laboratories by 3.1% during the 3rd quarter.
MML Investors Services LLC now owns 5,361 shares of the medical research company’s stock valued at $1,794,000 after purchasing an additional 159 shares during the last quarter. Retirement Systems of Alabama increased its holdings in Bio-Rad Laboratories by 416.9% during the 3rd quarter.
Retirement Systems of Alabama now owns 23,260 shares of the medical research company’s stock worth $7,782,000 after purchasing an additional 18,760 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Bio-Rad Laboratories by 95.
6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after purchasing an additional 21,669 shares during the last quarter.
65.24% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades BIO has been the topic of several analyst reports.
StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.
00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.
00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.
com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $395.20. Bio-Rad Laboratories Trading Up 5.
7 % NYSE BIO opened at $245.43 on Friday. The business’s fifty day moving average is $264.
86 and its 200-day moving average is $314.80. The company has a debt-to-equity ratio of 0.
18, a current ratio of 6.48 and a quick ratio of 4.85.
The stock has a market capitalization of $6.87 billion, a price-to-earnings ratio of -3.77 and a beta of 1.
12. Bio-Rad Laboratories, Inc. has a one year low of $215.
38 and a one year high of $387.99. Bio-Rad Laboratories ( NYSE:BIO – Get Free Report ) last announced its quarterly earnings data on Thursday, February 13th.
The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.
04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.
90%. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.
81 EPS for the current year. About Bio-Rad Laboratories ( Free Report ) Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics.
The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. Further Reading Five stocks we like better than Bio-Rad Laboratories What Does Downgrade Mean in Investing? Robinhood Strategies Could Be a Game-Changer for Young Investors Stock Market Upgrades: What Are They? Are These 3 Retail Stocks Oversold or Really in Trouble? What is a Special Dividend? IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc.
( NYSE:BIO – Free Report ). Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter .
.
